Pre Close Trading Update

Celsis International PLC
19 March 2003

                            CELSIS INTERNATIONAL PLC

                            Pre Close Trading Update


Celsis International plc ('Celsis'), a world leading cGMP laboratory services
and rapid microbial testing company, whose diagnostic systems detect and measure
contamination, for the pharmaceutical, personal care, dairy and beverage
industries, will announce preliminary results for the year ending 31st March
2003 on 22nd May 2003.

Jay LeCoque, CEO, making the following comment on trading in the second half of
the year, said:

'Despite the current uncertainties in world markets, we have continued our
robust trading into the second half of our financial year.  Our restructured
business units have solidified our core operations, enabling us to build upon
these revitalized platforms to secure new growth across all market segments.

'We are pleased with the progress being made despite the difficult worldwide
economic environment and I am happy to report Group profits in line with market
expectations'


                                                                 19th March 2003


Enquiries:

Celsis International plc                            Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications


College Hill                                        Tel: [phone]
Nicholas Nelson


Notes to editors:

Celsis International plc (www.celsis.com) is a world leader in the development
and supply of rapid diagnostic and monitoring systems to detect and measure
microbial contamination in finished products bound for consumers.  It has
successfully developed tests for use in the pharmaceutical, cosmetic and
toiletries, food and beverage industries and is associated with some of the
best-known high street brands in these consumer areas.

These tests are based upon the years of research in enzyme technology that
employ numerous methods for the rapid detection of microbial contamination.  The
result is that microbial testing times are reduced from around five days to a
little over one day, thus lending significant cost advantages to Celsis'
customers.

Celsis International plc also has a leading cGMP laboratory services, supporting
the R&D and manufacturing based testing needs of the pharmaceutical,
biotechnology and personal care industries.  This business unit currently
operates primarily in the United States.


                      This information is provided by RNS
            The company news service from the London Stock Exchange